Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2025 10:07 ET | Source: Pluristyx, Inc.

Pluristyx and Solesis Announce Strategic Collaboration to Advance Organoid and Cell Therapy Solutions

Pluristyx and Solesis partner to launch game-changing standardized organoid kits, powered by iPSC and polymer technologies.
September 22, 2025 06:20 ET | Source: CELLPROTHERA

CellProthera annonce la publication de ses résultats de phase I/IIb sur la sécurité et la faisabilité des ProtheraCytes® chez des patients souffrant d'insuffisance cardiaque sévère après un infarctus du myocarde.

La publication du JACC-Heart Failure souligne la haute qualité de l'expansion cellulaire, la bonne tolérance, le risque procédural gérable et les signes précoces encourageants d'effets fonctionnels. ...
September 22, 2025 06:20 ET | Source: CELLPROTHERA

CellProthera announces peer-reviewed publication of its Phase I/IIb results on safety and feasibility of ProtheraCytes® in patients with severe heart failure post-myocardial Infarction

JACC-Heart Failure publication highlights high-quality cell expansion, good tolerability, manageable procedural risk and encouraging early signals of functional effects. Mulhouse, France – [DATE] –...
September 04, 2025 07:07 ET | Source: Pluristyx, Inc.

Pluristyx and BioLamina Announce Strategic Partnership to Accelerate Development of Stem Cell-Based Therapies

Pluristyx & BioLamina partner to accelerate iPSC-based therapies with integrated cell culture solutions, for consistency, scalability & clinical success.
August 13, 2025 16:05 ET | Source: Longeveron

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated...
July 21, 2025 09:15 ET | Source: Longeveron

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron licenses patented stem cell technology from the University of Miami.
July 08, 2025 09:15 ET | Source: Longeveron

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.
June 26, 2025 09:05 ET | Source: Longeveron

Longeveron® Appoints Than Powell as Chief Business Officer

Than Powell appointed as Longeveron CBO to lead overall business strategy, Alzheimer's program partnering and HLHS program international strategy.
January 22, 2025 13:55 ET | Source: BCC Research LLC

Induced Pluripotent Stem Cells Industry Poised for 9.1% CAGR Growth by 2028

Boston, Jan. 22, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Induced Pluripotent Stem Cells: Global Markets is expected to reach $5.2 billion by the end of 2028, at a...
January 21, 2025 09:28 ET | Source: Cell BioEngines, Inc.

Cell BioEngines Announces Establishment of New R&D Facility to Further Advance Its Platform and Pipeline of Innovative Cell Therapies

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc. (“Cell BioEngines” or the “Company”), a clinical-stage biotechnology company developing a universal ‘plug-and-play’ allogeneic stem...